peeyam
- 08 May 2007 11:30
LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.
Financial details of the deal were not disclosed.
The partners plan to enter into a global licence arrangement for the technology.
Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.
In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.
Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels
As usual, pls do ur own research.
blanche
- 18 Aug 2009 10:01
- 186 of 1204
We are going to have a beer in the pub first and talk about all the money we are making. Giving it high fives and stuff!
Global Nomad
- 18 Aug 2009 10:14
- 187 of 1204
honesty is a wonderful thing cynic. enjoy.
moneyplus
- 18 Aug 2009 10:37
- 188 of 1204
Cynic may I take a bow-glad you've done well! I pointed it out to you on the other thread--gkp I think. Answers to other comments --yes it does lower blood pressure dramatically in some cases and can replace medication obviously doctors should be consulted to monitor for this as you have to drink it daily to benefit fully. It apparently lowers blood pressure within an hour---smooths platelets and is really good to take before flying to prevent dvt. Hence the rumoured interest from airlines, a food co. called DGM has a large stake and coca cola is in the wings.
EFSA have approved the product but the wording has to be medically/technically correct when promoting it before deals etc can go ahead. This is what the excitement is all about and it seems the sky is the limit---I very much hope!! If I read any more I'll report back but the provexis web site is worth looking at for their other treatments. We've come a long way since they made aspirin from a foxglove but this is their area of expertise. wowee!!!
Global Nomad
- 18 Aug 2009 10:54
- 189 of 1204
DSM - top 3 food global ingredients supplier and food tech development. holds 28%.
cynic
- 18 Aug 2009 11:00
- 190 of 1204
aspirin from foxglove? .... i thought it was digitalis for lactating mothers!
VIJAY128
- 18 Aug 2009 11:08
- 191 of 1204
De Ja Vue the graph indicates a similar run to yesterday. Traget raised to 12p
Global Nomad
- 18 Aug 2009 11:10
- 192 of 1204
found something re market and licenses for anti-thrombotic and platelet aggregation inhibitors; selected paragraphs here, link below. I'm not a pharmasist/expert - so this may be parallel - but still gives sense of license deals/market size. there is a hint of decling market but this is still huge.
February 27, 2009
decision by Novartis to license phase II anti-clotting agent elinogrel from private US biotech Portola Pharmaceuticals for USD 75 million upfront.
Although the full terms of the deal were not disclosed, the upfront fee suggests this is the biggest product deal in this field since Pfizer licensed apixaban, whilst in phase III trials, from Bristol-Myers Squibb for USD 250 million upfront in April 2007.
However, the patent expiry for Plavix, the industrys second biggest product in 2008 with sales of USD 9.43 billion behind Lipitor at USD 12.4 billion, means that revenues for this class of drug are forecast to decline seven percent annually to USD 8.1 billion by 2014.
full article here;
http://www.ebdgroup.com/partneringnews/?q=node/153
moneyplus
- 18 Aug 2009 14:25
- 193 of 1204
oops you're right cynic--digitalis from foxgloves for heart disease I think. Aspirin comes from some plant I think but just can't remember!
jkd
- 18 Aug 2009 16:00
- 194 of 1204
m
aspirin comes from the bark of a tree,cant remember which one. however this may ,or may not, explain the old witches brew which contained the bark of a tree plus "other" ingrediants,maybe those other ingredients might also be proven in time. i think one of those "brews" included frogs.
no doubt someone might enlighten us.
regards
jkd
diggingdeep
- 18 Aug 2009 16:07
- 195 of 1204
http://www.moneyam.com/InvestorsRoom/posts.php?tid=14368#lastread
jkd
- 18 Aug 2009 16:25
- 196 of 1204
dd
if you are going to spam at least make it easy for me. Lol
regards
jkd
edit thanks ian and team
blanche
- 18 Aug 2009 17:08
- 197 of 1204
25% up today! Iam happy with that. Got to be some rns tmrw. imho
moneyplus
- 18 Aug 2009 18:33
- 198 of 1204
I bought my orange/pomegranate sirco today in H&B sales are going very well and the assistant was very interested to know what effect the drink had on consumers and why it's selling well. very pleased with the rise today so took out my original stake and will let the rest run long term. Hoodless is utter rubbish couldn't sell even 25k online with them!
skyhigh
- 19 Aug 2009 08:46
- 199 of 1204
as a long term holder..(from 3.65p a few yrs ago but also topped up at 1p recently) .....I'm continuing to hold.... I sold a few the other day at6p as I needed some cash...
Will stay in whatever the outcome (long term should be fantastic).....
the past week has been fun and would rather be in than out !
pinechris
- 19 Aug 2009 08:56
- 200 of 1204
Been in from about 18 months ago at about 2p, sold yesterday at 6p as I couldn't see the rise continuing, will get back in at some point as I think the potential is huge.
halifax
- 19 Aug 2009 15:46
- 201 of 1204
sp falling rapidly is this yet another over ramped share?
cynic
- 19 Aug 2009 15:49
- 202 of 1204
greedy tossers like me have been deservedly nibbled!
fortunately not a huge amount at stake even if sp goes to zero, but isn't there a post somewhee mentioning an AGM or similar in the near future.
halifax
- 19 Aug 2009 16:05
- 203 of 1204
cynic will it bottom at 3p?
skinny
- 19 Aug 2009 16:08
- 204 of 1204
cynic
- 19 Aug 2009 16:14
- 205 of 1204
halifax asking the arch tosser's opinion - whatever next??!!
i see the hoped-for support at 3p, but whether or not it holds remains to be seen